ArticleInternational journal of molecular sciences2026
Chrono-Nanomedicine at the Barrier: Circadian Rhythms Influence the Delivery of Donepezil Across the BCSFB.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
To reach the target tissue within the central nervous system (CNS), drugs, such as donepezil (DNPZ), must overcome naturally occurring barriers. Despite its substantial pharmacological relevance, the blood-cerebrospinal fluid barrier (BCSFB) remains insufficiently studied. The BCSFB harbors a functional molecular clock that regulates, for instance, the expression of membrane transporters. Thus, there has been an increasing interest in exploring chronotherapeutic strategies to enhance cerebral drug delivery. Additionally, nanotechnology constitutes a well-established approach for improving tissue-specific drug bioavailability within the CNS through, for example, the employment of chitosan (CS)-based nanosystems. Given the considerable potential of both approaches for the treatment of neurological disorders, we propose establishing an integrated chronotherapy-nanotechnology platform to optimize pharmacological regimens. In this context, this study aims to explore the influence of circadian rhythms in the transport of free and encapsulated DNPZ forms across an in vitro model of the BCSFB. We developed and characterized CS-based nanoparticles with promising properties for the enhanced delivery of DNPZ across brain barriers. We found that free and encapsulated drug forms of DNPZ display distinct patterns of circadian trafficking across BCSFB. In summary, our findings represent an important step toward the integration of chronotherapy and nanotechnology as a promising strategy to optimize therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.